HIGHLIGHTS
- who: Report and collaborators from the Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA Hematology and Oncology have published the Article: Review began 09/20/2022 Review ended 09/26/2022 Published 09/29/2022 u00a9 Copyright, in the Journal: (JOURNAL) of September/29,/2022
- what: The analysis showed that there were durable benefits to patients in terms of spleen volume reductions, symptom relief, and reductions in JAK2 V617F allele burden, and a good proportion of patients had maintained or improved their BMF, which was notable in long-term ruxolitinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.